Page last updated: 2024-09-04

moxifloxacin and ondansetron

moxifloxacin has been researched along with ondansetron in 9 studies

Compound Research Comparison

Studies
(moxifloxacin)
Trials
(moxifloxacin)
Recent Studies (post-2010)
(moxifloxacin)
Studies
(ondansetron)
Trials
(ondansetron)
Recent Studies (post-2010) (ondansetron)
3,1575521,6903,3801,216994

Protein Interaction Comparison

ProteinTaxonomymoxifloxacin (IC50)ondansetron (IC50)
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)10
Solute carrier family 22 member 2Homo sapiens (human)1.295
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)10
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)10
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)10
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)10
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)10
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)10
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)10
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)10
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)10
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)10
5-hydroxytryptamine receptor 3ARattus norvegicus (Norway rat)0.0136
5-hydroxytryptamine receptor 2BHomo sapiens (human)0.717
5-hydroxytryptamine receptor 3AHomo sapiens (human)0.0001
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)10
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)10
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)10
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)0.7303
Multidrug and toxin extrusion protein 2Homo sapiens (human)2.4533
GABA theta subunitRattus norvegicus (Norway rat)10
Multidrug and toxin extrusion protein 1Homo sapiens (human)0.0875
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)10
5-hydroxytryptamine receptor 3BRattus norvegicus (Norway rat)0.0181

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (44.44)29.6817
2010's4 (44.44)24.3611
2020's1 (11.11)2.80

Authors

AuthorsStudies
Keserü, GM1
Nagashima, R; Nishikawa, T; Tobita, M1
Lombardo, F; Obach, RS; Waters, NJ1
Jia, L; Sun, H1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV1
Sen, S; Sinha, N1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Benson, C; Brown, R; Couderc, JP; Darpo, B; Dota, C; Ferber, G; Ferry, J; Jarugula, V; Keirns, J; Ortemann-Renon, C; Pham, T; Riley, S; Sarapa, N; Ticktin, M; Zareba, W1

Reviews

1 review(s) available for moxifloxacin and ondansetron

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Trials

1 trial(s) available for moxifloxacin and ondansetron

ArticleYear
Evaluation of the Effect of 5 QT-Positive Drugs on the JTpeak Interval - An Analysis of ECGs From the IQ-CSRC Study.
    Journal of clinical pharmacology, 2020, Volume: 60, Issue:1

    Topics: Arrhythmias, Cardiac; Biomarkers; Cetirizine; Drug-Related Side Effects and Adverse Reactions; Electrocardiography; Female; Fluoroquinolones; Healthy Volunteers; Heart Conduction System; Heart Rate; Humans; Indoles; Ion Channels; Long QT Syndrome; Male; Moxifloxacin; Ondansetron; Phenethylamines; Quinine; Quinolizines; Risk Assessment; Sulfonamides

2020

Other Studies

7 other study(ies) available for moxifloxacin and ondansetron

ArticleYear
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
    Bioorganic & medicinal chemistry letters, 2003, Aug-18, Volume: 13, Issue:16

    Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship

2003
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
    Bioorganic & medicinal chemistry letters, 2005, Jun-02, Volume: 15, Issue:11

    Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated

2005
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Support vector machines classification of hERG liabilities based on atom types.
    Bioorganic & medicinal chemistry, 2008, Jun-01, Volume: 16, Issue:11

    Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve

2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
    Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3

    Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations

2010
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:2

    Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship

2011